116 related articles for article (PubMed ID: 1377687)
1. Vitronectin regulates the synthesis and localization of urokinase-type plasminogen activator in HT-1080 cells.
Ciambrone GJ; McKeown-Longo PJ
J Biol Chem; 1992 Jul; 267(19):13617-22. PubMed ID: 1377687
[TBL] [Abstract][Full Text] [Related]
2. Plasminogen activator inhibitor type I stabilizes vitronectin-dependent adhesions in HT-1080 cells.
Ciambrone GJ; McKeown-Longo PJ
J Cell Biol; 1990 Nov; 111(5 Pt 1):2183-95. PubMed ID: 1699954
[TBL] [Abstract][Full Text] [Related]
3. Binding of urokinase to plasminogen activator inhibitor type-1 mediates cell adhesion and spreading.
Planus E; Barlovatz-Meimon G; Rogers RA; Bonavaud S; Ingber DE; Wang N
J Cell Sci; 1997 May; 110 ( Pt 9)():1091-8. PubMed ID: 9175705
[TBL] [Abstract][Full Text] [Related]
4. Urokinase-type plasminogen activator receptors associate with beta1 and beta3 integrins of fibrosarcoma cells: dependence on extracellular matrix components.
Xue W; Mizukami I; Todd RF; Petty HR
Cancer Res; 1997 May; 57(9):1682-9. PubMed ID: 9135008
[TBL] [Abstract][Full Text] [Related]
5. Localization of urokinase type plasminogen activator to focal adhesions requires ligation of vitronectin integrin receptors.
Wilcox-Adelman SA; Wilkins-Port CE; McKeown-Longo PJ
Cell Adhes Commun; 2000; 7(6):477-90. PubMed ID: 11051458
[TBL] [Abstract][Full Text] [Related]
6. Localization of urokinase to focal adhesions by human fibrosarcoma cells synthesizing recombinant vitronectin.
Wilcox SA; Reho T; Higgins PJ; Tominna-Sebald E; McKeown-Longo PJ
Biochem Cell Biol; 1996; 74(6):899-910. PubMed ID: 9164658
[TBL] [Abstract][Full Text] [Related]
7. The uPA receptor and the somatomedin B region of vitronectin direct the localization of uPA to focal adhesions in microvessel endothelial cells.
Salasznyk RM; Zappala M; Zheng M; Yu L; Wilkins-Port C; McKeown-Longo PJ
Matrix Biol; 2007 Jun; 26(5):359-70. PubMed ID: 17344041
[TBL] [Abstract][Full Text] [Related]
8. Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation.
Kjøller L; Kanse SM; Kirkegaard T; Rodenburg KW; Rønne E; Goodman SL; Preissner KT; Ossowski L; Andreasen PA
Exp Cell Res; 1997 May; 232(2):420-9. PubMed ID: 9168821
[TBL] [Abstract][Full Text] [Related]
9. Human endothelial cells grow poorly on vitronectin: role of PAI-1.
Underwood PA; Bean PA; Cubeddu L
J Cell Biochem; 2001 Apr 2-27; 82(1):98-109. PubMed ID: 11400167
[TBL] [Abstract][Full Text] [Related]
10. Specific binding of urinary-type plasminogen activator (u-PA) to vitronectin and its role in mediating u-PA-dependent adhesion of U937 cells.
Moser TL; Enghild JJ; Pizzo SV; Stack MS
Biochem J; 1995 May; 307 ( Pt 3)(Pt 3):867-73. PubMed ID: 7537960
[TBL] [Abstract][Full Text] [Related]
11. Regulation of urokinase plasminogen activator/plasmin-mediated invasion of melanoma cells by the integrin vitronectin receptor alphaVbeta3.
Khatib AM; Nip J; Fallavollita L; Lehmann M; Jensen G; Brodt P
Int J Cancer; 2001 Feb; 91(3):300-8. PubMed ID: 11169951
[TBL] [Abstract][Full Text] [Related]
12. The receptor for urokinase-type plasminogen activator regulates fibronectin matrix assembly in human skin fibroblasts.
Monaghan E; Gueorguiev V; Wilkins-Port C; McKeown-Longo PJ
J Biol Chem; 2004 Jan; 279(2):1400-7. PubMed ID: 14602715
[TBL] [Abstract][Full Text] [Related]
13. Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin.
Waltz DA; Natkin LR; Fujita RM; Wei Y; Chapman HA
J Clin Invest; 1997 Jul; 100(1):58-67. PubMed ID: 9202057
[TBL] [Abstract][Full Text] [Related]
14. Coordinated expression of the vitronectin receptor and the urokinase-type plasminogen activator receptor in metastatic melanoma cells.
Nip J; Rabbani SA; Shibata HR; Brodt P
J Clin Invest; 1995 May; 95(5):2096-103. PubMed ID: 7537755
[TBL] [Abstract][Full Text] [Related]
15. Prourokinase activation on the surface of human rhabdomyosarcoma cells: localization and inactivation of newly formed urokinase-type plasminogen activator by recombinant class 2 plasminogen activator inhibitor.
Pöllänen J; Vaheri A; Tapiovaara H; Riley E; Bertram K; Woodrow G; Stephens RW
Proc Natl Acad Sci U S A; 1990 Mar; 87(6):2230-4. PubMed ID: 2138329
[TBL] [Abstract][Full Text] [Related]
16. Affinity purification of active plasminogen activator inhibitor-1 (PAI-1) using immobilized anhydrourokinase. Demonstration of the binding, stabilization, and activation of PAI-1 by vitronectin.
Wun TC; Palmier MO; Siegel NR; Smith CE
J Biol Chem; 1989 May; 264(14):7862-8. PubMed ID: 2470735
[TBL] [Abstract][Full Text] [Related]
17. Urokinase binding and catabolism by Hep G2 cells is plasminogen activator inhibitor-1 dependent, analogous to interactions of tissue-type plasminogen activator with these cells.
Grimsley PG; Normyle JF; Brandt RA; Joulianos G; Chesterman CN; Hogg PJ; Owensby DA
Thromb Res; 1995 Aug; 79(4):353-61. PubMed ID: 7482438
[TBL] [Abstract][Full Text] [Related]
18. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins.
Czekay RP; Aertgeerts K; Curriden SA; Loskutoff DJ
J Cell Biol; 2003 Mar; 160(5):781-91. PubMed ID: 12615913
[TBL] [Abstract][Full Text] [Related]
19. alpha(v)beta(3) integrin engagement modulates cell adhesion, proliferation, and protease secretion in human lymphoid tumor cells.
Vacca A; Ria R; Presta M; Ribatti D; Iurlaro M; Merchionne F; Tanghetti E; Dammacco F
Exp Hematol; 2001 Aug; 29(8):993-1003. PubMed ID: 11495705
[TBL] [Abstract][Full Text] [Related]
20. Endogenous receptor-bound urokinase mediates tissue invasion of the human lung carcinoma cell lines A549 and Calu-1.
Bruckner A; Filderman AE; Kirchheimer JC; Binder BR; Remold HG
Cancer Res; 1992 Jun; 52(11):3043-7. PubMed ID: 1375533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]